Syncom Formulation (India) Ltd. (IN:SYNCOMF)
:SYNCOMF
Want to see IN:SYNCOMF full AI Analyst Report?
Top Page
Syncom Formulation (India) Ltd.
(SYNCOMF)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹17.50
▲(25.18% Upside)
Action:Reiterated
Date:05/26/26
The score is driven primarily by improved FY2026 profitability and a sharply strengthened, low-debt balance sheet. Technicals are supportive with price above major moving averages and a positive MACD, but an overbought RSI raises near-term risk. Valuation is moderate on P/E, with no dividend data to add support.
Positive Factors
De-risked, very low‑leverage balance sheet
A dramatic reduction in debt and equity expansion materially improves solvency and financial optionality. Low leverage lowers refinancing and interest risk, supports working capital and capex, and gives management flexibility for strategic investments or opportunistic M&A over the medium term.
Negative Factors
Top‑line decline in FY2026
A 5% revenue drop after prior expansion suggests demand weakness or loss of momentum. Without clear new product launches or channel gains, top‑line contraction can limit the durability of recent profit improvements and constrains ability to achieve scale economies over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
De-risked, very low‑leverage balance sheet
A dramatic reduction in debt and equity expansion materially improves solvency and financial optionality. Low leverage lowers refinancing and interest risk, supports working capital and capex, and gives management flexibility for strategic investments or opportunistic M&A over the medium term.
Read all positive factors
Syncom Formulation (India) Ltd. (SYNCOMF) vs. iShares MSCI India ETF (INDA)
Market Cap
₹14.89B
Dividend YieldN/A
Average Volume (3M)249.72K
Price to Earnings (P/E)12.7
Beta (1Y)1.57
Revenue Growth4.98%
EPS Growth55.05%
CountryIN
Employees998
SectorServices
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.69
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.34
Price to Sales (P/S)1.99
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syncom Formulation (India) Ltd. Business Overview & Revenue Model
Company Description
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer...
How the Company Makes Money
Syncom Formulations (India) Ltd. primarily makes money by selling pharmaceutical formulations it manufactures. Key revenue streams generally include: (1) Sales of finished dosage formulations under the company’s own brands through pharmaceutical d...
Syncom Formulation (India) Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
88
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.15B | 4.89B | 4.65B | 2.63B | 2.24B | 2.18B |
| Gross Profit | 1.70B | 1.31B | 1.58B | 559.50M | 825.58M | 709.74M |
| EBITDA | 819.28M | 774.30M | 711.74M | 430.28M | 341.47M | 319.59M |
| Net Income | 630.52M | 764.38M | 494.35M | 253.14M | 200.71M | 197.90M |
Balance Sheet | ||||||
| Total Assets | 4.56B | 5.34B | 4.13B | 4.05B | 3.78B | 3.08B |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 1.13B | 899.28M | 1.32B | 708.97M | 402.47M |
| Total Debt | 6.97M | 14.74M | 45.84M | 724.87M | 831.82M | 577.91M |
| Total Liabilities | 775.88M | 1.19B | 711.23M | 1.17B | 1.22B | 860.17M |
| Stockholders Equity | 3.78B | 4.15B | 3.42B | 2.88B | 2.56B | 2.22B |
Cash Flow | ||||||
| Free Cash Flow | 461.83M | 452.54M | 134.77M | -140.95M | -101.05M | 50.16M |
| Operating Cash Flow | 560.11M | 569.24M | 234.36M | -59.58M | 105.29M | 163.29M |
| Investing Cash Flow | -524.72M | -506.23M | -182.04M | 830.20M | -449.53M | -270.73M |
| Financing Cash Flow | -39.76M | -18.66M | -679.03M | -145.58M | 350.01M | 82.94M |
Syncom Formulation (India) Ltd. Technical Analysis
Positive
13.98
Price Trends
13.21
Positive
13.21
Positive
14.89
Positive
Market Momentum
0.48
Negative
72.42
Negative
69.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNCOMF, the sentiment is Positive. The current price of 13.98 is below the 20-day moving average (MA) of 14.26, above the 50-day MA of 13.21, and below the 200-day MA of 14.89, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 72.42 is Negative, neither overbought nor oversold. The STOCH value of 69.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SYNCOMF.
Syncom Formulation (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹25.21B | 12.63 | ― | 3.06% | 21.45% | 78.77% | |
73 Outperform | ₹14.89B | 12.72 | ― | ― | 4.98% | 55.05% | |
63 Neutral | ₹12.06B | 35.45 | ― | ― | 9.29% | -16.45% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
40 Underperform | ₹9.11B | -186.71 | ― | 0.85% | -2.75% | -89.51% |
* Services Sector Average
IN:SYNCOMF
Syncom Formulation (India) Ltd.
16.02
-6.01
-27.28%
IN:GRPLTD
GRP Ltd
1,720.75
-1,211.27
-41.31%
IN:KMEW
Knowledge Marine & Engineering Works Limited
2,153.40
1,388.78
181.63%
IN:MMWL
Media Matrix Worldwide Limited
13.40
2.11
18.69%
IN:UDS
Updater Services Limited
181.55
-155.70
-46.17%
IN:UNIPARTS
Uniparts India Ltd.
608.25
295.70
94.61%
Syncom Formulation (India) Ltd. Corporate Events
Syncom Formulations Promoters File Annual SEBI SAST Shareholding Disclosure
Apr 6, 2026
Syncom Formulations (India) Ltd. has reported that its promoters, Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda, along with persons acting in concert, have submitted their annual shareholding disclosure for the financial year ended 31 Mar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.